组合建筑市场：现况分析与预测（2023-2030）

Combivir 是拉米夫定和齐多夫定组合的品牌名称，用于治疗人类免疫缺陷病毒/后天免疫缺乏症候群 (HIV)。这些药物作为抗逆转录病毒药物，透过竞争性抑製或降低逆转录□的活性来对抗爱滋病毒。1997年获得美国食品药物管理局（FDA）批准。由于无保护性行为、共用受污染的针头和注射器以及对爱滋病毒传播方式缺乏认识等因素，导致爱滋病毒诊断和治疗日益普遍，Combivir 受到市场关注。例如，《Pan African Medical Journal》2021年发表的一份关于埃塞俄比亚南部Kembata Tembaro Zone公立医院抗逆转录病毒治疗期间爱滋病毒感染的报告发现，无保护性行为的发生率为40.9%，其中女性49.4%为男性， 31.5%为男性。几个因素包括政府关于爱滋病毒传播方式和可用治疗方法的宣传计划的激增、口服药物需求的增加、吸毒成瘾率的上升以及政府、公共和私营部门对卫生部门的投资增加。预测期内的市场成长。根据国家药物滥用统计中心的数据，12岁以上的人中有一半至少使用过一次非法药物，2020年联邦药物管制预算为350亿美元。

由于需要遏制爱滋病患者的快速成长，全球製药公司加大研发投入，Combivir 市场预计将稳定成长 3% 左右。例如，据美国癌症研究所估计，2021 年全球将有 3 万癌症患者。其他几个因素，例如仿製药的引入、其成本效益以及政府措施也在稳步推动这一 Combivir 市场的发展。例如，美国卫生与公众服务部 (HHS) 于 2019 年启动了结束爱滋病毒流行 (EHE) 计划，其雄心勃勃的目标是到 2030 年将美国新发爱滋病毒感染人数减少 90%。HHS 也为司法管辖区提供多种资助机会，包括对性传染病诊所的同时投资。

按类型划分，市场分为品牌产品和通用产品。2022年，在全球组合建筑市场中，品牌细分市场将占最大份额。由于该品牌的良好声誉，该细分市场在市场上占据主导地位。因此，许多消费者纷纷涌向品牌药品。因此，由于上述原因，品牌细分市场将在 2022 年占据主要市场份额。

根据应用，市场分为非职业暴露和职业暴露。由于工作量、工作时间长和时间压力导致医疗中心的伤亡人数不断增加，职业暴露细分市场预计在预测期内将占据相当大的市场份额。例如，商业情报公司Definitive Healthcare在2022年发布报告称，2021年，估计有33.3万名医护人员报告职业倦怠程度高、工作时间长、患者工作量繁重。他表示，自己离职是因为这个的。除此之外，越来越多的毒瘾病例增加了医院的病患负担，也推动了这一领域的成长。因此，在应用中，职业暴露类别预计在预测期内将出现较高的复合年增长率。

为了更了解Combivir的市场介绍，市场为北美（美国、加拿大、北美其他地区）、欧洲（德国、英国、法国、西班牙、义大利、欧洲其他地区）、亚太地区（中国、日本、印度） ） 。，亚太地区其他地区），以及世界其他地区中东和非洲。由于爱滋病毒感染人数不断增加、毒瘾增加以及开发有效治疗方法的投资不断增加，到 2022 年，北美将占据全球 Combivir 市场的大部分。政府机构已启动爱滋病宣传计划，为病患提供有效的照护。例如，美国《2022-2025 年国家爱滋病毒/爱滋病战略》旨在对所有公民进行有关爱滋病毒/爱滋病的教育，包括爱滋病毒传播、预防和构成最大感染风险的行为。因此，2022年北美将占据很大的市场份额。

目录

第一章 市场介绍

• 市场定义
• 主要目标
• 利益相关者
• 限制

第二章 研究方法或假设

• 调查过程
• 调查方法
• 受访者简介

第三章市场总结

第 4 章执行摘要

第五章 COVID-19 对组合建筑市场的影响

第六章 组合建筑市场收入，2020-2030

第 7 章按类型划分的市场洞察

• 牌
• 通用的

第 8 章按应用划分的市场洞察

• 非职业暴露
• 职业接触

第 9 章按地区划分的市场洞察

• 北美
  • 美国
  • 加拿大
  • 北美其他地区
• 欧洲
  • 德国
  • 英国
  • 法国
  • 意大利
  • 西班牙
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 亚太其他地区
• 世界其他地区 中东/非洲

第10章组合建筑市场动态

• 市场驱动力
• 市场挑战
• 影响分析

第十一章 Combi 建构市场机会

第十二章组合建筑市场趋势

第十三章需求面与供给面分析

• 需求面分析
• 供给侧分析

第十四章价值链分析

第15章 竞争场景

• 竞争格局
  • 波特五力分析

第十六章公司简介

• Mylan Inc.
• Macleods Pharmaceuticals Ltd.
• Lupin
• Aurobindo Pharma
• Pfizer Inc.
• Cipla Inc.
• ViiV Healthcare group of companies
• Hetero
• Strides Pharma Science Limited
• GSK plc.

第十七章 免责声明

Combivir is the brand name for a combination of drugs lamivudine and zidovudine used to treat Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV). These drugs act as antiretroviral agents and fight against HIV by competitively inhibiting and reducing the activity of reverse transcriptase. It was initially approved in 1997 by the U.S. Food and Drug Administration. Combivir is gaining prominence in the market owing to the increasing prevalence of HIV diagnosis and treatment due to unprotected coitus, sharing of contaminated needles or syringes, absence of awareness about the mode of transmission of HIV. For instance, in 2021, according to the Pan African Medical Journal's report of HIV on antiretroviral therapy in public hospitals of Kembata Tembaro Zone, Southern Ethiopia, the prevalence of unprotected sex was (40.9%) among which there were 49.4% of females and 31.5% of males. Several factors, including a surge in the increasing government awareness programs regarding the mode of transmission of HIV and available treatment options for HIV, rising demand for oral drugs, rising drug addiction rate, and increased investments from the government, public, and private sectors in healthcare departments are driving the growth of the market during the forecast period. According to the National Center for Drug Abuse Statistics, half of people 12 and older have used illicit drugs at least once and the federal budget for drug control in 2020 was USD 35 billion.

The Combivir Market is expected to grow at a steady rate of around 3% owing to the increased investment in research & development globally by pharmaceutical companies due to the surge in AIDS cases which needs to be controlled. For instance, according to U.S. HIV.gov, in 2021, there were 32,100 estimated new HIV infections in the U.S. Many new therapies are being introduced for treating this deadly retrovirus. Several other factors, such as the introduction of generic drugs and their cost-effectiveness, and government initiatives are also driving this market of combivir at a steady rate. For instance, the U.S.-based Department of Health and Human Services (HHS) initiated a program the ' Ending the HIV Epidemic (EHE)' in 2019 with an ambitious goal of reducing all new HIV infections in the U.S. by 90% by 2030. HHS has also provided multiple funding opportunities to jurisdictions, including simultaneous investments in sexually transmitted diseases specialty clinics.

Based on type, the market is bifurcated into branded and generic. The branded segment held the maximum share in the global market of combivir in 2022. This segment dominated the market because of their good brand reputation . This draws a maximum number of consumers towards branded drugs. Hence, due to the above reasons, the branded segment held a significant share of the market in 2022.

Based on application, the market is bifurcated into nonoccupational exposure and occupational exposure. The occupational exposure segment is expected to hold a significant share of the market in the forecast period owing to the increased number of casualties in healthcare centers owing to workload, long working hours, and time pressure. For instance, a commercial intelligence company Definitive Healthcare published a report in 2022 saying an estimated 333,000 healthcare providers left their jobs in 2021, due to burnout, long hours, and heavy patient loads. Apart from this, the rising number of cases of drug addiction is boosting the patient load in hospitals and is also impelling the growth of this segment. Hence, amongst applications, the occupational exposure category is expected to witness higher CAGR during the forecast period.

For a better understanding of the market adoption of combivir, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America dominated the global combivir market in the year 2022 due to the increasing HIV cases, increasing drug addiction, and rising number of investments in developing effective therapeutics. Government organizations are initiating AIDS awareness programs to provide efficient care to patients. For instance, the U.S.-based National HIV/AIDS Strategy for 2022-2025 aims to educate all its citizens regarding HIV/AIDS including HIV transmission, prevention, and behaviors that place individuals at greatest risk for infection. Thus, North America held a significant share of the market in the year 2022.

Some of the major players operating in the market include: Mylan Inc.; Macleods Pharmaceuticals Ltd.; Lupin; Aurobindo Pharma; Pfizer Inc.; Cipla Inc.; ViiV Healthcare group of companies; Hetero; Strides Pharma Science Limited; GSK plc.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Combivir Market
• 2.2. Research Methodology of the Combivir Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE COMBIVIR MARKET

6 COMBIVIR MARKET REVENUE (USD BN), 2020-2030F

7 MARKET INSIGHTS BY TYPE

• 7.1. Branded
• 7.2. Generic

8 MARKET INSIGHTS BY APPLICATIONS

• 8.1. Nonoccupational Exposure
• 8.2. Occupational Exposure

9 MARKET INSIGHTS BY REGION

• 9.1. North America
  • 9.1.1. U.S.
  • 9.1.2. Canada
  • 9.1.3. Rest of North America
• 9.2. Europe
  • 9.2.1. Germany
  • 9.2.2. U.K.
  • 9.2.3. France
  • 9.2.4. Italy
  • 9.2.5. Spain
  • 9.2.6. Rest of Europe
• 9.3. Asia-Pacific
  • 9.3.1. China
  • 9.3.2. Japan
  • 9.3.3. India
  • 9.3.4. Rest of Asia-Pacific
• 9.4. Rest of World

10 COMBIVIR MARKET DYNAMICS

• 10.1. Market Drivers
• 10.2. Market Challenges
• 10.3. Impact Analysis

11 COMBIVIR MARKET OPPORTUNITIES

12 COMBIVIR MARKET TRENDS

13 DEMAND AND SUPPLY-SIDE ANALYSIS

• 13.1. Demand Side Analysis
• 13.2. Supply Side Analysis

14 VALUE CHAIN ANALYSIS

15 COMPETITIVE SCENARIO

• 15.1. Competitive Landscape
  • 15.1.1. Porters Fiver Forces Analysis

16 COMPANY PROFILED

• 16.1. Mylan Inc.
• 16.2. Macleods Pharmaceuticals Ltd.
• 16.3. Lupin
• 16.4. Aurobindo Pharma
• 16.5. Pfizer Inc.
• 16.6. Cipla Inc.
• 16.7. ViiV Healthcare group of companies
• 16.8. Hetero
• 16.9. Strides Pharma Science Limited
• 16.10. GSK plc.

17 DISCLAIMER